Archives
-
Takeda Pharmaceuticals Seeks Approval for COVID-19 Treatment
Early this month, Takeda announced that they are starting the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) for COVID-19 treatment. The drug is named TAK-888. Hyperimmune globulin is a plasma derived-therapy that has previously treated several acute viral respiratory infection and has the potential to treat patients with COVID-19.
Latest Research Articles
-
Ted Halstead: Climate Change - What Is It?
-
Disasters that Can Affect Your Way of Life
-
Caring for Dogs (and Cats) in Times of Coronavirus
-
Smell of Ocean Plastic is Attractive to Sea Turtles - Study
-
Entrepreneur Pitches Safety Nailer in 'Shark Tank' Episode
-
Where on Earth Did the King Penguins Go?
-
Fungus Causes High Mortality in Hibernating North American Bats
-
The Role of Blood Test in the Fight Against the Coronavirus Pandemic
-
Climate Change Study Reveals: Blame the Rich
-
Young Adults are Not Invincible to COVID-19, CDC Warns
-
CDC, WHO, and Biotech Companies: The Critical Need for Quicker Coronavirus Testing
-
How to Find the Right Car Accident Attorney for You
most popular
-
Beyond the Aurora: How Do Solar Flares Affect Electronics
-
WhaleX Team Creates Synthetic Whale Poop to Revive Ocean Ecosystems
-
Catastrophic Wildfire in New York Kills 18-Year-Old Park Employee, Triggers Unhealthy Air Readings
-
Microplastics Could Form Clouds and Severely Affect Weather, Climate
-
Antarctica’s 'Doomsday Glacier' May Get Protection Barrier in Effort to Prevent Flooding
